Age-related systemic treatment and survival of patients with metachronous metastases from colorectal cancer

References

• Surveillance, Epidemiology, and End Results Program (SEER). Available from: http://seer.cancer.gov/statfacts [last accessed 2016].
   Google Scholar
• Lemmens V, van Steenbergen L, Janssen-Heijnen M, et al. Trends in colorectal cancer in the south of the Netherlands 1975-2007: rectal cancer survival levels with colon cancer survival. Acta Oncol 2010;49:784–96.
   PubMed Web of Science ®Google Scholar
• Meulenbeld HJ, van Steenbergen LN, Janssen-Heijnen ML, et al. Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004. Ann Oncol 2008;19:1600–4.
   PubMed Web of Science ®Google Scholar
• Galandiuk S, Wieand HS, Moertel CG, et al. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1992;174:27–32.
   PubMedGoogle Scholar
• Manfredi S, Bouvier AM, Lepage C, et al. Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population. Br J Surg 2006;93:1115–22.
   PubMed Web of Science ®Google Scholar
• Obrand DI, Gordon PH. Incidence and patterns of recurrence following curative resection for colorectal carcinoma. Dis Colon Rectum 1997;40:15–24.
   PubMed Web of Science ®Google Scholar
• Guyot F, Faivre J, Manfredi S, et al. Time trends in the treatment and survival of recurrences from colorectal cancer. Ann Oncol 2005;16:756–61.
   PubMed Web of Science ®Google Scholar
• van Gestel YR, de Hingh IH, van Herk-Sukel MP, et al. Patterns of metachronous metastases after curative treatment of colorectal cancer. Cancer Epidemiol 2014;38:448–54.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Lenz HJ, Kohne CH, et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 2015;33:692–700.
   PubMed Web of Science ®Google Scholar
• Jennens RR, Giles GG, Fox RM. Increasing underrepresentation of elderly patients with advanced colorectal or non-small-cell lung cancer in chemotherapy trials. Intern Med J 2006;36:216–20.
   PubMed Web of Science ®Google Scholar
• UICC. TNM classification of malignant tumors. 7th ed. Wiley-Blackwell: New York, 2009.
   Google Scholar
• Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet 2000;355:1041–7.
   PubMed Web of Science ®Google Scholar
• Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. Irinotecan Study Group. 2000;343:905–14.
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938–47.
   PubMed Web of Science ®Google Scholar
• Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:136–47.
   PubMed Web of Science ®Google Scholar
• Seymour MT, Thompson LC, Wasan HS, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomized factorial trial. Lancet 2011;377:1749–59.
   PubMed Web of Science ®Google Scholar
• Aparicio T, Lavau-Denes S, Phelip JM, et al. Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02)dagger. Ann Oncol 2016;27:121–7.
   PubMed Web of Science ®Google Scholar
• Grothey A, Sargent D, Goldberg RM, et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004;22:1209–14.
   PubMed Web of Science ®Google Scholar
• Ducreux M, Malka D, Mendiboure J, et al. Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000-05): an open-label, randomized, phase 3 trial. Lancet Oncol 2011;12:1032–44.
   PubMed Web of Science ®Google Scholar
• Seymour MT, Maughan TS, Ledermann JA, et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomized controlled trial. Lancet 2007;370:143–52.
   PubMed Web of Science ®Google Scholar
• Tomita Y, Karapetis CS, Ullah S, et al. Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry. Acta Oncol 2016;55:480–5.
   PubMed Web of Science ®Google Scholar
• Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomized controlled trial. Lancet 2007;370:135–42.
   PubMed Web of Science ®Google Scholar
• Sorbye H, Berglund A, Tveit KM, et al. Secondary treatment and predictive factors for second-line chemotherapy after first-line oxaliplatin-based therapy in metastatic colorectal cancer. Acta Oncol 2007;46:982–8.
   PubMed Web of Science ®Google Scholar
• Wagner AD, Arnold D, Grothey AA, et al. Anti-angiogenic therapies for metastatic colorectal cancer. Cochrane Database Syst Rev 2009;3:CD005392.
   Google Scholar
• Kabbinavar FF, Hurwitz HI, Yi J, et al. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 2009;27:199–205.
   PubMed Web of Science ®Google Scholar
• Kozloff M, Yood MU, Berlin J, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist 2009;14:862–70.
   PubMed Web of Science ®Google Scholar
• Cunningham D, Lang I, Marcuello E, et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomized phase 3 trial. Lancet Oncol 2013;14:1077–85.
   PubMed Web of Science ®Google Scholar
• Rosati G, Aprile G, Cardellino GG, et al. A review and assessment of currently available data of the EGFR antibodies in elderly patients with metastatic colorectal cancer. J Geriatr Oncol 2016;7:134–41.
   PubMed Web of Science ®Google Scholar
• Sastre J, Massuti B, Pulido G, et al. First-line single-agent panitumumab in frail elderly patients with wild-type KRAS metastatic colorectal cancer and poor prognostic factors: a phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumors. Eur J Cancer 2015;51:1371–80.
   PubMed Web of Science ®Google Scholar
• Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229–37.
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23–30.
   PubMed Web of Science ®Google Scholar
• Hammerman A, Greenberg-Dotan S, Battat E, et al. The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study. Acta Oncol 2015;54:164–70.
   PubMed Web of Science ®Google Scholar
• Sorbye H, Cvancarova M, Qvortrup C, et al. Age-dependent improvement in median and long-term survival in unselected population-based Nordic registries of patients with synchronous metastatic colorectal cancer. Ann Oncol 2013;24:2354–60.
   PubMed Web of Science ®Google Scholar